Some new amino substituted quinazoline compounds were synthesized and evaluated for their anticancer activity at National Cancer Institute (NCI), U.S.A. Among the synthesized nine compounds, two were selected for single high dose screening (10-5 M) in full 60 cell panel. Among the selected compounds, 2-benzamido-N-(benzo[d]thiazol-2-yl)benzamide 4 exhibited significant anticancer activity against non-small cell lung cancer NCI-H23, colon cancer HCT-15, CNS cancer SF-539, melanoma SK-MEL-5, ovarian cancer OVCAR-8, renal cancer ACHN, prostate cancer PC-3 and breast cancer MCF7 with inhibition rate of 97.82%, 99.67%, 99.21%, 90.75%, 99.21%, 99.31%, 97.23% and 93.29% respectively. This compound was selected for testing under five dose level screening against 60 cancer cell lines. The results of five dose assay revealed significant anticancer activity of this compound against almost all cancer cell lines.